Blog

Andean Precious Metals (TSE:APM) reported a record first quarter for 2026, with management citing higher production, stronger realized gold and silver prices, and improved performance across its

Automotive Properties Real Est Invt TR (TSE:APR.UN) reported higher first-quarter revenue and cash flow, with management citing the impact of acquisitions completed in 2025 and early 2026, along

AutoCanada (TSE:ACQ) reported first-quarter 2026 adjusted EBITDA from continuing operations of CAD 31 million, down from CAD 43 million a year earlier, as the company continued to work through a

Aimia (TSE:AIM) said its first quarter was marked by progress on the planned sale of specialty chemicals business Bozzetto, continued efforts to reduce holding company costs and a weaker sales

Tecogen (OTCMKTS:TGEN) reported lower first-quarter revenue and a wider loss as management said the company is investing in research, marketing and manufacturing capacity tied to its push into the

Netlist (OTCMKTS:NLST) reported record quarterly revenue for the first quarter of 2026, citing strong demand for memory products, tight industry supply and higher DRAM pricing as key drivers of its

• 3 Stocks With High ROE and Market-Beating Growth Potential

Docebo (NASDAQ:DCBO) is seeing improved enterprise demand after addressing product and go-to-market gaps that weighed on its business in

• MarketBeat Week in Review – 08/18 - 08/22

CSX (NASDAQ:CSX) Executive Vice President and Chief Financial Officer Kevin Boone said the railroad remains focused on improving margins, capturing pricing

BioStem Technologies (OTCMKTS:BSEM) said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company’s focus from physician

Ascend Wellness (OTCMKTS:AAWH) reported first-quarter 2026 results that management said came in ahead of its guidance, as the cannabis operator pointed to improving retail mix, higher vertical

• MarketBeat Week in Review – 08/18 - 08/22

CSX (NASDAQ:CSX) used its 2026 annual meeting of shareholders to highlight early-year operating momentum after what executives described as a difficult

Xtant Medical (NYSEAMERICAN:XTNT) raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter

Americas Gold and Silver (NYSEAMERICAN:USAS) reported what management described as a strong start to 2026, citing record consolidated silver production, sharply higher revenue and progress on

WidePoint (NYSEAMERICAN:WYY) reported higher first-quarter revenue, positive adjusted EBITDA and its first quarterly net income since 2021, while management said the company’s 2026 outlook remains

• Shocking uranium play that hedge funds kept hidden

Ur Energy (NYSEAMERICAN:URG) said production momentum improved at its Lost Creek uranium operation during the first quarter of 2026 and that its

• Is This Pre-IPO AI Robotics Company the Next Big Defense Play?

Unusual Machines (NYSEAMERICAN:UMAC) reported sharply higher first-quarter 2026 revenue and said it is continuing to expand capacity

• Standard Lithium Stock is Breaking New Levels

Standard Lithium (NYSEAMERICAN:SLI) executives said the company remains on track to reach a final investment decision and begin construction in 2026 at

• 3 Underrated Robotics Stocks Poised for Huge Gains

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition

Titan Mining (NYSEAMERICAN:TII) said its first-quarter results reflected steady zinc operations, early progress in graphite shipments and a new effort to evaluate germanium recovery through a

Radiant Logistics (NYSEAMERICAN:RLGT) reported higher net income for its fiscal third quarter ended March 31, 2026, while adjusted earnings measures declined from the prior-year period, as

• 3 Biotech Stocks That Could Benefit from the Patent Cliff

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch

Pedevco (NYSEAMERICAN:PED) reported first-quarter 2026 results that management said exceeded internal expectations in the company’s first full quarter following its merger with Juniper, with higher

Orla Mining (NYSEAMERICAN:ORLA) reported a strong start to 2026, with management saying first-quarter production, permitting progress and exploration results positioned the gold producer to meet

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen